A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT07384975. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study). Participants will: * Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion). * Visit the clinic up to 9 times for checkups and tests over 22 weeks. * Complete a daily diary about their skin pain.
Study identification
- NCT ID
- NCT07384975
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 4, 2026
- Primary completion
- Aug 31, 2027
- Completion
- Sep 30, 2027
- Last update posted
- Jul 21, 2026
2026 – 2027
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Medical Dermatology Specialist | Phoenix | Arizona | 85006 | Recruiting |
| Scottsdale Clinical Trials | Scottsdale | Arizona | 85260 | Recruiting |
| Accel Research Sites Network | Maitland | Florida | 32751 | Recruiting |
| Floridian Research Institute | Miami | Florida | 33179 | Recruiting |
| Cordova Research Institute | Miami | Florida | 33182 | Recruiting |
| Ziaderm Research, LLC | North Miami Beach | Florida | 33162 | Recruiting |
| FWD Clinical Research | Tamarac | Florida | 33321 | Recruiting |
| MplusM - D&H Tamarac Research Center | Tamarac | Florida | 33321 | Recruiting |
| ForCare Clinical Research | Tampa | Florida | 33613 | Recruiting |
| Kentucky Advanced Medical Research LLC | Murray | Kentucky | 42071 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Recruiting |
| SKY Integrative Medical Center | Ridgeland | Mississippi | 39157 | Recruiting |
| StracSkin, PLLC | Portsmouth | New Hampshire | 03801 | Recruiting |
| Equity Medical, LLC | The Bronx | New York | 10455 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
Recently updated Hidradenitis Suppurativa (HS) trials
Other public records listing Hidradenitis Suppurativa (HS). Sorted by last update posted; newest first. Not a recommendation.
- NCT07783542: ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa Not yet recruiting
- NCT07766005: A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) Not yet recruiting
- NCT07756346: A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa Not yet recruiting
- NCT07748169: An Observational Study of Patients With Dermatologic Disease Recruiting
- NCT07689188: Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa Not yet recruiting
- NCT07263230: The Safety and Efficacy of Roflumilast Foam in HS Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07384975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Jul 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07384975 live on ClinicalTrials.gov.